Summary
Researchers are studying whether a targeted medicine called sacituzumab tirumotecan (also known as MK-2870), used alone or with other treatments, can treat certain gastrointestinal (GI) cancers.
The cancers being studied are either advanced or metastatic (have spread to other parts of the body) or unresectable (cancer cannot be removed with surgery).
The goals of this study are to learn:
- How safe the treatment is and how well people tolerate it
- How many people have their cancer respond to treatment (shrink or go away)
You may be eligible if you have one of the following cancers:
- Unresectable or metastatic colorectal cancer, and have received prior treatment
- Advanced or metastatic pancreatic cancer and have received prior treatment
- Advanced and/or unresectable biliary tract cancer (you may or may not have received prior treatment)
Eligible participants will be allocated to one of three treatment groups.
- Arm 1: Sacituzumab tirumotecan + chemotherapy
- Arm 2: Sacituzumab tirumotecan alone
- Arm 3: Sacituzumab tirumotecan + cisplatin chemotherapy + pembrolizumab immunotherapy
In all arms, participants will continue to receive the treatment until the cancer gets worse or they don't tolerate treatment.
Conditions
This trial is treating people with advanced or metastatic colorectal cancer, pancreatic ductal adenocarcinoma, or biliary tract cancer